MA27069A1 - FORMES POLYMORPHES DE RIFAXIMIN, PROCEDES POUR LEUR PRODUCTION ET USAGE DE MeME DANS LES PREPARATIONS MEDICINALES - Google Patents

FORMES POLYMORPHES DE RIFAXIMIN, PROCEDES POUR LEUR PRODUCTION ET USAGE DE MeME DANS LES PREPARATIONS MEDICINALES

Info

Publication number
MA27069A1
MA27069A1 MA27590A MA27590A MA27069A1 MA 27069 A1 MA27069 A1 MA 27069A1 MA 27590 A MA27590 A MA 27590A MA 27590 A MA27590 A MA 27590A MA 27069 A1 MA27069 A1 MA 27069A1
Authority
MA
Morocco
Prior art keywords
rifaximin
production
medicinal preparations
crystallization
forms
Prior art date
Application number
MA27590A
Other languages
English (en)
Inventor
Giuseppe C Viscomi
Manuela Campana
Dario Braga
Donatella Confortini
Vincenzo Cannata
Denis Severini
Paolo Righi
Goffredo Rosini
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27069(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of MA27069A1 publication Critical patent/MA27069A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMES POLYMORPHES DE RIFAXIMIN, PROCESSUS DE LEUR PRODUCTION ET DE LEUR EMPLOI DANS LES PREPARATIONS MEDICINALES Des formes cristallines polymorphes de l'antibiotique rifaximin (INN) dites rifaximin (alpha) et rifaximin (beta), et une forme faiblement cristalline appelée rifaximin (upsilon), ont été découvertes. Ces formes sont utiles dans la production des préparations médicinales pour l'usage oral et topique, et peuvent être obtenues au moyen d'un processus de cristallisation effectué par dissolvant chaud de rifaximin brute dans alcool de l'éthyle et en entraînant la cristallisation du produit par l'addition d'eau à une température déterminée pendant une période déterminée. La cristallisation est poursuivie par un séchage effectué sous des conditions contrôlées jusqu'à ce que le produit fini atteint une teneur d'eau spécifique.
MA27590A 2003-11-07 2004-03-24 FORMES POLYMORPHES DE RIFAXIMIN, PROCEDES POUR LEUR PRODUCTION ET USAGE DE MeME DANS LES PREPARATIONS MEDICINALES MA27069A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e

Publications (1)

Publication Number Publication Date
MA27069A1 true MA27069A1 (fr) 2004-12-20

Family

ID=33187382

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27590A MA27069A1 (fr) 2003-11-07 2004-03-24 FORMES POLYMORPHES DE RIFAXIMIN, PROCEDES POUR LEUR PRODUCTION ET USAGE DE MeME DANS LES PREPARATIONS MEDICINALES

Country Status (38)

Country Link
US (5) US7045620B2 (fr)
EP (6) EP1676847B1 (fr)
JP (5) JP2005139161A (fr)
KR (4) KR20050043589A (fr)
CN (4) CN1613858A (fr)
AR (3) AR043547A1 (fr)
AT (3) ATE421965T1 (fr)
AU (2) AU2004200964A1 (fr)
BR (2) BRPI0402382A (fr)
CA (2) CA2460384A1 (fr)
CL (1) CL2004000498A1 (fr)
CO (1) CO5560083A1 (fr)
CY (3) CY1108017T1 (fr)
DE (4) DE04005541T1 (fr)
DK (3) DK1676847T3 (fr)
ES (3) ES2244364T3 (fr)
HK (3) HK1092151A1 (fr)
HR (2) HRP20040265A2 (fr)
IL (2) IL160798A0 (fr)
IT (1) ITMI20032144A1 (fr)
JO (1) JO2470B1 (fr)
MA (1) MA27069A1 (fr)
MD (1) MD3653G8 (fr)
ME (1) ME00424B (fr)
MX (2) MXPA04002353A (fr)
NO (1) NO334950B1 (fr)
NZ (1) NZ531622A (fr)
PL (3) PL1557421T3 (fr)
PT (3) PT1557421E (fr)
RS (4) RS20060168A (fr)
RU (1) RU2270200C2 (fr)
SI (3) SI1557421T1 (fr)
TN (2) TNSN04044A1 (fr)
TW (1) TWI285107B (fr)
UA (1) UA86384C2 (fr)
WO (1) WO2005044823A2 (fr)
YU (1) YU24804A (fr)
ZA (1) ZA200401948B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
SI1698630T1 (sl) * 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
JP5844961B2 (ja) 2006-08-02 2016-01-20 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線直腸ｓ状結腸炎を処置するための組成物および方法
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
KR101667534B1 (ko) * 2006-09-22 2016-10-19 씨아이피엘에이 엘티디. 리팍시민
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
ES2389358T5 (es) * 2007-07-06 2016-01-19 Lupin Ltd. Composiciones farmacéuticas de rifaximina
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
SG10201607926VA (en) * 2008-02-25 2016-11-29 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
US11779571B2 (en) * 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
US20110065741A1 (en) 2009-02-26 2011-03-17 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
KR20100122937A (ko) * 2008-02-26 2010-11-23 샐릭스 파마슈티컬스 리미티드 장 질환의 치료 방법
WO2009137672A1 (fr) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Procédés de traitement de maladie intestinale par l’administration d’un nettoyant d’intestin et d’un antibiotique
US8980872B2 (en) 2008-09-26 2015-03-17 Aska Pharmaceutical Co., Ltd. Agent for preventing and/or treating functional gastrointestinal disorder
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
HUE065491T2 (hu) 2008-10-02 2024-05-28 Salix Pharmaceuticals Ltd A hepatikus enkefalopátia kezelése rifaximin alkalmazásával
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
ES2718614T3 (es) 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
WO2011005388A1 (fr) * 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Procédés de traitement de l'encéphalopathie hépatique
NZ599944A (en) * 2009-10-27 2015-10-30 Lupin Ltd Solid dispersion of rifaximin
WO2011061748A1 (fr) * 2009-11-19 2011-05-26 Strides Arcolab Limited Prémélange à base de rifaximine
CA2781580A1 (fr) 2009-11-23 2011-05-26 Cipla Limited Composition de mousse topique
WO2011080691A1 (fr) 2009-12-28 2011-07-07 Silvio Massimo Lavagna Procédés pour la production de rifaximine amorphe
CA2789929C (fr) 2010-02-18 2019-11-26 Salix Pharmaceuticals, Ltd. Procedes pour traiter l'infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
KR20130086338A (ko) * 2010-06-03 2013-08-01 샐릭스 파마슈티컬스 리미티드 리팍시민의 신규한 형태들 및 이들의 용도
WO2011156897A2 (fr) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Formes polymorphiques de rifaximine
ES2801678T3 (es) * 2010-07-12 2021-01-12 Salix Pharmaceuticals Inc Formulaciones de rifaximina y sus usos
US8759513B2 (en) 2010-09-13 2014-06-24 Sequent Scientific Limited Polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (fr) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Procédé de préparation de rifaximine amorphe
WO2012076832A1 (fr) * 2010-12-09 2012-06-14 Cipla Limited Suppositoires contenant de la rifaximine
US8735419B2 (en) * 2011-02-11 2014-05-27 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
EP2705042A1 (fr) 2011-05-02 2014-03-12 Ranbaxy Laboratories Limited Solvate de diméthylformamide rifaximine
WO2012155981A1 (fr) 2011-05-19 2012-11-22 Friulchem Spa Nouveau procédé pour la synthèse de rifaximine et nouvelle forme pseudo-cristalline de rifaximine obtenue au moyen de celui-ci
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
PL2773205T3 (pl) * 2011-11-02 2024-09-02 Salix Pharmaceuticals, Inc. Ryfaksymina w leczeniu ustępującej biegunki z przewagą zespołu jelita drażliwego
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
WO2013185211A1 (fr) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Formes polymorphes de rifaximine
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (fr) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Compositions pharmaceutiques de rifaximine
MX2015011802A (es) 2013-03-15 2016-01-08 Alfa Wassermann Spa Rifaximina para usarse en el tratamiento de infecciones vaginales.
US20160047819A1 (en) 2013-03-15 2016-02-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
PL2983647T3 (pl) 2013-04-12 2021-01-25 Alfasigma S.P.A. Podawanie nlpz oraz związane z tym składniki, sposoby i układy
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
EP2927235B1 (fr) * 2014-03-31 2017-02-08 Euticals S.P.A. Mélange de polymorphes de rifaximine et son utilisation pour la préparation de formulations solides
EP3134415A4 (fr) 2014-04-19 2017-10-25 Granules India Limited Procédé amélioré pour la préparation de dérivés de la rifamycine
CN106795192B (zh) 2014-05-04 2020-06-16 萨利克斯药品公司 Ibs微生物群及其用途
WO2015173697A1 (fr) 2014-05-12 2015-11-19 Alfa Wassermann S.P.A. Nouvelle forme cristalline solvatée de la rifaximine, production, compositions et utilisations associées
WO2016003536A1 (fr) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Procédés pour le retraitement du syndrome du côlon irritable
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (fr) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification de bactérie vaginale
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (fr) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Procédé de préparation de formes cristallines de rifaximine
HUE040253T2 (hu) 2016-03-24 2019-02-28 Sandoz Ag Rifaximin alfa&deltát tartalmazó gyógyászati készítmény
HUE044432T2 (hu) 2016-03-24 2019-10-28 Sandoz Ag Rifaximin alfá-t tartalmazó, hosszan eltartható kompozíció
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
EP3518924B1 (fr) 2016-09-30 2022-08-10 Salix Pharmaceuticals, Inc. Formes de dispersions solides de rifaximine
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
EP3416627B9 (fr) 2017-04-26 2020-04-22 Sandoz AG Forme posologique orale comprenant de la rifaximine sous forme bêta
ES2868180T3 (es) 2017-06-26 2021-10-21 Biofer Spa Derivados de pirido-imidazo rifamicina como agentes antibacterianos
CA3142214A1 (fr) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Utilisation de methylnaltrexone et de rifaximine pour le traitement d'une permeabilite intestinale accrue ou de troubles associes
CA3151010A1 (fr) 2019-09-24 2021-04-01 Arturo J. Angel Formulations liquides de rifaximine
US20230116647A1 (en) 2020-03-24 2023-04-13 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (fr) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorphe de la rifaximine, son procédé de préparation et composition pharmaceutique contenant de la rifaximine
US20230277447A1 (en) 2020-06-26 2023-09-07 Bausch Health Ireland Limited Targeted release rifaximin compositions
WO2022090490A1 (fr) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Formulations liquides de rifaximine destinées à être utilisées dans le traitement de la drépanocytose

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (fr) 1984-05-15 1986-12-30 Vincenzo Cannata Nouvelle methode pour la synthese d'imidazorifamycines
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
EP0536197B1 (fr) * 1990-06-29 1995-07-26 GRUPPO LEPETIT S.p.A. Rifapentine sous forme cristalline pure
EP1248869A2 (fr) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. Formation, identification et analyse a productivites elevees de formes solides diverses
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
EP1330427A1 (fr) * 2000-10-31 2003-07-30 Ciba SC Holding AG Formes cristallines de chlorhydrate de venlafaxine
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
KR101667534B1 (ko) * 2006-09-22 2016-10-19 씨아이피엘에이 엘티디. 리팍시민
WO2008115572A1 (fr) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Procédés et compositions d'ains
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
ES2389358T5 (es) 2007-07-06 2016-01-19 Lupin Ltd. Composiciones farmacéuticas de rifaximina
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミンの薬剤組成物
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
SG10201607926VA (en) 2008-02-25 2016-11-29 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof

Also Published As

Publication number Publication date
MXPA06002644A (es) 2006-06-06
CN101260115A (zh) 2008-09-10
KR20060110737A (ko) 2006-10-25
SI1676848T1 (sl) 2009-06-30
MD3653F2 (en) 2008-07-31
ES2244364T3 (es) 2007-12-01
EP2210893A1 (fr) 2010-07-28
US20080132530A1 (en) 2008-06-05
ES2244364T1 (es) 2005-12-16
JP5199576B2 (ja) 2013-05-15
IL160798A0 (en) 2004-08-31
EP1676848A1 (fr) 2006-07-05
CN1886408B (zh) 2010-06-09
CN101260114A (zh) 2008-09-10
PL1676847T3 (pl) 2009-07-31
CN101260115B (zh) 2011-11-23
BRPI0407149A (pt) 2006-02-07
HK1092151A1 (en) 2007-02-02
BRPI0407149A8 (pt) 2019-01-15
DE602004019298D1 (de) 2009-03-19
EP1676848B1 (fr) 2009-01-28
DE602004019296D1 (de) 2009-03-19
TWI285107B (en) 2007-08-11
DK1676848T3 (da) 2009-05-11
PT1676847E (pt) 2009-04-09
US8173801B2 (en) 2012-05-08
YU24804A (sh) 2006-08-17
EP1557421A1 (fr) 2005-07-27
CL2004000498A1 (es) 2005-03-11
EP1676847A1 (fr) 2006-07-05
DK1676847T3 (da) 2009-05-11
RU2270200C2 (ru) 2006-02-20
PT1676848E (pt) 2009-04-09
WO2005044823A2 (fr) 2005-05-19
BRPI0402382A (pt) 2005-06-28
TNSN04044A1 (en) 2006-06-01
NZ531622A (en) 2004-10-29
ATE361927T1 (de) 2007-06-15
KR20050043589A (ko) 2005-05-11
NO20061110L (no) 2006-04-19
EP1557421B1 (fr) 2007-05-09
CY1108964T1 (el) 2014-07-02
CA2538546C (fr) 2011-04-19
RS20150291A1 (en) 2015-10-30
HRP20060093B1 (hr) 2015-12-18
CA2538546A1 (fr) 2005-05-19
US8404704B2 (en) 2013-03-26
US7915275B2 (en) 2011-03-29
SI1676847T1 (sl) 2009-06-30
KR20070113326A (ko) 2007-11-28
MD20060080A (en) 2006-11-30
CA2460384A1 (fr) 2005-05-07
ZA200401948B (en) 2004-04-29
CO5560083A1 (es) 2005-09-30
CN1886408A (zh) 2006-12-27
SI1557421T1 (sl) 2007-08-31
ME00424B (fr) 2011-10-10
RS20060168A (en) 2008-09-29
DE602004006367T2 (de) 2007-09-06
AR081991A2 (es) 2012-10-31
ES2320161T3 (es) 2009-05-19
DE04005541T1 (de) 2005-12-29
PT1557421E (pt) 2007-07-31
US20120059023A1 (en) 2012-03-08
JP2005139161A (ja) 2005-06-02
KR100855084B1 (ko) 2008-08-29
AU2004287601B8 (en) 2009-03-05
US20050101598A1 (en) 2005-05-12
RS54568B1 (en) 2016-06-30
RS54571B1 (en) 2016-06-30
PL1557421T3 (pl) 2007-08-31
DK1557421T3 (da) 2007-09-17
CN101260114B (zh) 2012-11-28
JP2011046738A (ja) 2011-03-10
RS20150292A1 (en) 2015-10-30
JP2011057698A (ja) 2011-03-24
ATE421965T1 (de) 2009-02-15
KR100883216B1 (ko) 2009-02-13
PL1676848T3 (pl) 2009-07-31
UA86384C2 (uk) 2009-04-27
TNSN06069A1 (en) 2007-10-03
WO2005044823A3 (fr) 2005-10-27
HK1073657A1 (en) 2005-10-14
HK1092150A1 (en) 2007-02-02
AR043547A1 (es) 2005-08-03
CY1108909T1 (el) 2014-07-02
TW200515913A (en) 2005-05-16
EP2208730A1 (fr) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
IL174271A (en) 2010-12-30
HRP20060093A2 (en) 2006-05-31
AU2004200964A1 (en) 2005-05-26
ATE421966T1 (de) 2009-02-15
AU2004287601A1 (en) 2005-05-19
US20050272754A1 (en) 2005-12-08
EP1682556A2 (fr) 2006-07-26
US7045620B2 (en) 2006-05-16
ES2320160T4 (es) 2011-03-09
RS54569B1 (en) 2016-06-30
JP5635376B2 (ja) 2014-12-03
JP2007509904A (ja) 2007-04-19
DE602004006367D1 (de) 2007-06-21
IL174271A0 (en) 2006-08-01
CY1108017T1 (el) 2013-09-04
AU2004287601B2 (en) 2009-02-26
KR20070113327A (ko) 2007-11-28
ITMI20032144A1 (it) 2005-05-08
MD3653G8 (ro) 2016-08-31
MXPA04002353A (es) 2005-05-11
RU2004108953A (ru) 2005-10-27
EP1676847B1 (fr) 2009-01-28
US20110160449A1 (en) 2011-06-30
JO2470B1 (en) 2009-01-20
NO334950B1 (no) 2014-08-04
JP2014177500A (ja) 2014-09-25
KR100867751B1 (ko) 2008-11-10
CN1613858A (zh) 2005-05-11
AR081992A2 (es) 2012-10-31
DE602004006367C5 (de) 2019-04-04

Similar Documents

Publication Publication Date Title
MA27069A1 (fr) FORMES POLYMORPHES DE RIFAXIMIN, PROCEDES POUR LEUR PRODUCTION ET USAGE DE MeME DANS LES PREPARATIONS MEDICINALES
EP1484328B1 (fr) Dérivés de la quinolyl propyl piperidine et leur utilisation en tant qu' agents antimicrobiens
CN102076681A (zh) 作为治疗剂的取代γ-内酰胺
NZ242191A (en) Crystalline tiagabine hydrochloride monohydrate, preparation and pharmaceutical compositions thereof
US20060264636A1 (en) Salts of clopidogrel and process for preparation
JP2005529120A (ja) ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
CN102007098A (zh) 治疗性的取代的环戊烷
BRPI0607436B1 (pt) Base cristalina do composto trans-1-((1r,3s)-6-cloro-3-fenil-indan1-il)-3,3-dimetil-piperazina, sua composição farmacêutica, seus usos, seu método de preparação, método para fabricação do referido composto, bem como base livre do referido composto
DE602004006268T2 (de) Substituierte diketopiperazine und deren verwendung als oxytocynantagonisten
JP2005523245A5 (fr)
CA2469918A1 (fr) Procede de preparation de derives d'echinocandines et leurs compositions
EA008907B1 (ru) Производные индола
FR2753970A1 (fr) Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
EP1487790B1 (fr) Lasofoxifene purifie et procede de purification du lasofoxifene racemique
JPH08253479A (ja) 抗片頭痛性インドリルアルキル−ピリジニルおよびピリミジニルピペラジンの１，２，５−チアジアゾール誘導体
JPH08504828A (ja) 置換（アリールアルキルアミノベンジル）アミノプロピオンアミド誘導体及びその製造方法
HUT74671A (en) Novel (1-phenyl-1-heterocyclyl) methanol and (1-phenyl-1-heterocyclyl) methylamine derivatives and pharmaceutical compositions containing them
FR2678269A1 (fr) Derives de 1-(4-chlorophenyl)-2-[4-(2-phenylethyl)piperidin-1-yl]ethanol, leur application et leur preparation en therapeutique.
FR2862967A1 (fr) Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
ES2284078T3 (es) Procedimiento para la redisolucion de nefopam.
FR2672286A1 (fr) Derives de 1-(4-chlorophenyl)-2-[4-(phenylmethyl)piperidin-1-yl]ethanol, leur preparation et leur application en therapeutique.
EP0463970A1 (fr) Nouveaux dérivés d'oxazolo pyridines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
CA1112642A (fr) Derives de l'isoquinoleine, leur preparation et les compositions qui les contiennent
JP4322317B2 (ja) シングルエナンチオマーナルウェジンの製造方法
CA2175395A1 (fr) Indanylpiperazines ou homopiperazines, agents melatonergiques